ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Therapeutic potential of Aloe vera in diabetes mellitus treatment: an update.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetes mellitus is a metabolic disease manifested by hyperglycemia, leading to critical health challenges in the kidneys, eyes, nerves, and cardiovascular system. Aloe vera (Aloe barbadensis miller), a traditionally used herbal plant for treating various diseases, contains abundant bioactive compounds like alkaloids, flavonoids, acemannans, anthraquinones, chromones, anthrones, enzymes, vitamins, and minerals. These compounds are responsible for its diverse biological activities, including antimicrobial, anticancer, antidiabetic, anti-inflammatory, antioxidant, and hypolipidemic etc. This review primarily focuses on diabetes treatment through enzyme inhibition and modulation of metabolic parameters, with additional emphasis on diabetic complications including, the wound healing efficacy of Aloe vera. This study aims to evaluate the potential of Aloe vera in managing diabetes and minimizing the chances of diabetes-related organ damage. It was done by inhibition of several enzymes, including α-glucosidase, α-amylase, dipeptidyl peptidase-4, pancreatic lipase, sucrase, and maltase enzymes, both in vivo and in vitro. The previous research revealed that administrating various doses of Aloe vera-based extracts via orally and non-orally routes in streptozotocin-induced diabetes offered metabolic regulation of signaling pathways like blood sugar, insulin, lipid profile, body weight, oxidative stress, TNF-α, and IL-6 levels. Moreover, clinical data have confirmed Aloe vera's potential in diabetic wound healing by promoting tissue regeneration mechanisms like angiogenesis, fibrinogenesis, collagen synthesis, and inflammation to reduce lesion size. These therapeutic properties highlight the hypoglycemic nature of Aloe vera, promising its potential for future clinical use as an alternative for diabetes treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.